Nivolumab

Red

Brand Name(s):OPDIVO

Indication:Locally advanced or metastatic squamous non-small-cell lung cancer after chemotherapy

Non-locally advanced or metastatic squamous non-small-cell lung cancer after chemotherapy small cell lung cancer (NSCLC) advanced or metastatic

Melanoma – advanced treatment in adults (unresectable or metastatic)

Renal Cell Carcinoma (RCC) – advanced
Hodgkin lymphoma (relapsed or refractory classical after autologous stem cell transplant in adults).

Rationale:1,2,3,8

Considered:Jul-15

Review Date:Nov-25

Comments:
TA655 NICE guidance states: Nivolumab is recommended for locally advanced or metastatic squamous non-small-cell lung cancer after chemotherapy, only if they have not had a PD 1 or PD L1 inhibitor before, and it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses. Drug Safety Update
Reports of organ transplant rejection
Jul-17
…………………………
NICE TA417
Nivolumab for previously treated advanced renal cell carcinoma
Nov-16
…………………………
NICE TA400
Nivolumab in combination with ipilimumab for treating advanced melanoma
July 2016
…………………………
NICE TA 384
February 2016